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Abstract
LITAF is a 161 amino acid cellular protein which includes a proline rich N-terminus and a conserved C-terminal domain
known as the simple-like domain. Mutations in LITAF have been identified in Charcot-Marie tooth disease, a disease
characterized by protein aggregates. Cells transfected with cellular LITAF reveal that LITAF is localized to late endosomes/
lysosomes. Here we investigated the intracellular localization of endogenous LITAF. We demonstrated that endogenous
LITAF accumulates at a discrete cytoplasmic site in BGMK cells that we identify as the aggresome. To determine the domain
within LITAF that is responsible for the localization of LITAF to aggresomes, we created a construct that contained the C-
terminal simple-like domain of LITAF and found that this construct also localizes to aggresomes. These data suggest the
simple-like domain is responsible for targeting endogenous LITAF to the aggresome.
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Introduction
Lipopolysaccharide-induced tumor necrosis factor-alpha factor
(LITAF) is a small cellular protein comprised of 161 amino acids
with a currently unknown function [1]. LITAF is composed of two
very distinct termini. The N-terminus is proline rich and contains
proline rich binding sites (PPXY, (P(S/T)AP) for several proteins
including the E3 ligases neuronal precursor cell expressed
developmentally downregulated 4 (Nedd4) [2,3,4], Itch [2,3,4],
the E2 ubiquitin conjugating enzyme tumor suppressor gene 101
(TSG101) [3], and the putative tumor suppressor WW domain
oxidoreductase (WWOX) [5]. The C-terminus of LITAF is
cysteine rich and contains a C3H4-type zinc finger domain
interrupted by a stretch of 23 hydrophobic amino acids [1]. This
unique domain is termed the simple-like domain (SLD) and is
highly conserved throughout many eukaryotes. The SLD also
contains a YXXø (where ø is any hydrophobic amino acid) and a
dileucine motif [1]. Proteins containing YXXø motifs interact with
clathrin adaptor complexes to sort and target membrane proteins
throughout endosomes, the Golgi network, and lysosomes [6,7].
Furthermore, proteins containing dileucine motifs are also
commonly targeted to the endosome/lysosome network.
Although the cellular localization of LITAF appears to be
inconsistent between different cell types, its localization appears
consistently along the pathway of lysosomal degradation. Ectop-
ically expressed LITAF localizes within late endosomes/lysosomes
in BGMK, HEK 293T, COS-7, and THP-1 cell lines [1,4], the
Golgi apparatus in HEK 293T and MCF-7 cells [3,5], as well to
the plasma membrane in HEK 293T cells [3]. Endogenous
LITAF has only been reported in B lymphoblastoid cells where its
intracellular localization was not determined [3].
Our previous research revealed that recombinant LITAF
localized to the late endosome/lysosomes in BGMK cells [4]. Since




Endogenous LITAF localizes to a perinuclear region
within the cell
In order to determine cellular localization of endogenous LITAF,
BGMK cells were fixed and LITAF was detected using a mouse
polyclonal anti-LITAF antibody. We were able to detect endoge-
nous LITAF inBGMK cells (Figure 1).However, we were unableto
detect endogenous LITAF in a variety of other cell cells lines such as
HEK-293T, Hela cells, or primary neurons (data not shown).
Endogenous LITAF exhibited concentrated perinuclear staining,
which co-localized with c-tubulin (Figure 1) in all cells examined. c-
tubulin is a highly conserved protein found in the microtubule
organizing center (MTOC). In higher eukaryotes, the MTOC, or
centrosome, is composed of a pair of centrioles embedded in a matrix
of pericentriolar material (which includes c-tubulin) [8]. The region
of the cell that contains the MTOC is also the site of the aggresome.
Aggresomesare pericentriolar subcellular structuresencapsulated in a
vimentin sheath that contain aggregated misfolded ubiquitinated
proteins [9,10,11]. Aggresomes are formed when the degradation
capacity of the ubiquitin-proteasome system is overwhelmed and
misfolded proteins are transported from the periphery of the cell to
proteasomes that are located adjacent to the MTOC [9,10,11].
Since recombinant LITAF is localized to the late endosome/
lysosome, the site of protein degradation in the cell, we tested
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protein degradationinthe cell. Sincethe aggresomes areadjacent to
the MTOC, it is possible that LITAF is localized to the aggresome
rather than the MTOC. To test this hypothesis, we examined the
localization of LITAF with respect to the aggresome marker,
vimentin [9,10,11]. In BGMK cells, LITAF co-localizes with
vimentin in all cells examined (Figure 1). Localization of LITAF to
the pericentriolar region and with vimentin suggests that LITAF
localizes to a perinuclear region consistent with the aggresome.
Endogenous Nedd4 and LITAF co-localize at a
perinuclear site
Endogenous LITAF localizes to the MTOC/aggresome in
BGMK cells. Nedd4, an E3 ubiquitin ligase is a known binding
partner of LITAF [2,3]. We wanted to determine whether
endogenous Nedd4 co-localized with LITAF. In order to deter-
mine whether Nedd4 co-localizes along with LITAF, immunoflu-
orescence was performed using both anti-LITAF and anti-Nedd4
antibodies. We found that endogenous LITAF and Nedd4 co-
localized in every cell that expressed LITAF (Figure 1). These data
therefore suggest that endogenous LITAF is localized to the
MTOC/aggresome along with Nedd4 in BGMK cells.
Endogenous LITAF localizes to the aggresome
Since the MTOC and aggresome are immediately adjacent to
each other in the cell, it is difficult to discriminate whether
endogenous LITAF is targeted to the MTOC or the aggresome.
One method to discriminate between the MTOC and aggresome
is to look at LITAF localization during mitosis. During mitosis, the
centrosomes duplicate and move to the poles of the cell to
Figure 1. Endogenous LITAF accumulates in aggresomes. In order to detect endogenous LITAF, BGMK cells were fixed and indirect
immunofluorescence was performed. Anti-LITAF antibodies were used to detect endogenous LITAF (red), anti-Nedd4 antibodies were used to detect
Nedd4 (cyan), and anti-vimentin or anti-c-tubulin antibodies were visualized (blue) to determine localization of LITAF. Nuclei were visualized using
differential interference contrast (DIC) or ToPro (green). All images were taken using a laser scanning confocal microscope.
doi:10.1371/journal.pone.0030003.g001
Endogenous LITAF in Aggresomes
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30003segregate the chromosome pairs during metaphase. However, the
aggresome does not divide and remains as a single structure in
dividing cells that is inherited by one of the daughter cells [12]. In
the daughter cell that does not inherit an aggresome, a new
aggresome will eventually form as proteins destined for degrada-
tion begin to accumulate in the cell. Therefore, in order to clarify
whether LITAF localized to aggresomes or centrosomes, anti-
LITAF antibodies were used to visualize LITAF in BGMK cells.
An a-tubulin antibody was used to visualize the cellular
microtubule network during interphase and cell division. During
interphase, LITAF was localized at the center of the a-tubulin
network (Figure 2). However, during metaphase and anaphase of
mitosis LITAF was localized away from the mitotic spindle
(Figure 2). Finally, as the cells divide during cytokinesis, LITAF is
inherited by only one daughter cell (Figure 2). These results
suggest that LITAF is localized to aggresomes and not centro-
somes. During cell division, two centrosomes exist, one at each
pole of the cell. Therefore, if LITAF were associated with
centrosomes, then one would expect LITAF staining at two
separate locations. Aggresomes on the other hand are only
inherited by a single daughter cell [12]. The asymmetrical
inheritance of the aggresomes to only one cell generates different
cell fates and is thought to be of evolutionary advantage [12]. One
cell remains free of aggregated protein and any disease phenotype
the aggregated proteins cause. The asymmetric inheritance of
LITAF therefore suggests localization in aggresomes.
The simple-like domain (SLD) is responsible for targeting
LITAF to the aggresome
The SLD is a unique domain found in the C-terminus of
LITAF. It contains a RING finger domain interrupted by a stretch
of hydrophobic amino acids and the function of this domain
remains elusive [1]. In order to determine whether the SLD alone
was sufficient to target LITAF to aggresomes, we created two
LITAF constructs. The first construct represents a full-length
version of LITAF that was N-terminal FLAG-tagged. The Flag-tag
allows us to detect the transfected LITAF without detecting
endogenous LITAF. The second construct is a truncation of LITAF
composed of only the C-terminus of LITAF, which we term the
SLD (Figure 3A). The SLD construct was N-terminal myc-tagged.
BGMK cells were transfected with either full-length LITAF or the
SLD of LITAF. At 24 hours post-transfection, both LITAF and
SLD showed a punctate staining in the cytoplasm of the cell with a
high degree of co-localization (Figure 3B). We have previously
shown that transfected LITAF localized to the late endosome/
lysosome (Eaton et al., 2011). At 36 hours post-transfection, unlike
full length LITAF, SLD staining appeared to redistribute within the
Figure 2. Endogenous LITAF undergoes asymmetric inheritance. In order to determine whether LITAF localized to centrosomes or
aggresomes, BGMK cells were fixed and processed for indirect immunofluorescence. Cells were probed for endogenous LITAF (anti-LITAF antibodies;
red), anti-a-tubulin (green), and ToPRO (Invitrogen; blue) were used to visualize the mitotic stage of each cell during interphase or mitosis. White
arrows denote the sites of microtubule nucleation (MTOC).
doi:10.1371/journal.pone.0030003.g002
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(Figure 3B). Some co-localization still existed between the SLD
and LITAF, although it is less than that observed at 24 hours post-
transfection. At 48 hours post-transfection, the SLD staining
continued to concentrate in a perinuclear region (Figure 3B).
Although patches of expression of SLD where still seen outside of
the perinuclear region with regions that overlapped with full-length
LITAF. It should be noted that most of the full-length LITAF
staining did not overlap with the SLD.
Since the SLD over time localizes to a small perinuclear region
we decided to test whether the SLD was being targeted to the
aggresome. By 36 hours, the SLD appears to become less
associated with LITAF-positive compartment and more with
another structure in the cell. In order to determine where within
the cell the SLD was localizing to, the SLD construct was
transfected into cells and a variety of cellular markers were
examined. We found that the SLD staining coalesced around
endogenous LITAF and vimentin staining (Figure 4), suggesting
that the SLD is either forming around the aggresome or causing
an expansion of the aggresome. We also demonstrated that the
Golgi apparatus rearranged to form around SLD staining
(Figure 4), which is consistent with other studies that found the
Golgi apparatus surrounding aggresomes [9]. These results suggest
that overtime the SLD construct changes localization within the cell
and begins to converge in aggresomes, a site where endogenous
LITAF is localized. In addition, the localization of either
endogenous or ectopic LITAF, or the SLD was not affected by
the presence of the proteasome inhibitor MG132 (data not shown).
Discussion
The accumulation of protein aggregates is commonly linked with
disease-associated mutant misfolded proteins including huntingtin
[13], parkin [14] and peripheral myelin protein 22 (PMP22) [15].
Specifically, mutations or duplication of PMP22 increases its rate of
misfolding and accumulation in aggresomes, resulting in Charcot-
Marie Tooth (CMT) disease subtype 1A [15,16,17]. CMT is the
most common group of inherited neuropathies that result in muscle
weakness and progressive wasting [18]. There is extensive genetic
heterogeneity in CMT with over 20 causative genes identified,
including LITAF [19,20,21,22,23,24,25,26,27,28]. Mutations in
LITAF were recently identified as the molecular basis of CMT
Figure 3. Over-expression of the SLD results in perinuclear localization. (A) Schematic of full-length LITAF and the SLD showing the proline
rich N-terminus of LITAF (green) and the SLD is composed of a RING finger-like domain (cyan) which is interrupted with a hydrophobic domain (red).
(B) BGMK cells were transiently co-transfected with FLAG-LITAF and myc-SLD. Twenty-four, 36, and 48 hours after transfection, cells were fixed and
underwent indirect immunofluorescence. FLAG-LITAF was detected using an anti-FLAG antibody (red) and myc-SLD was detected using anti-myc
antibodies (green). Yellow shows regions where the two proteins co-localize.
doi:10.1371/journal.pone.0030003.g003
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does not alter the ecotopic localization of LITAF [3] suggesting that
the mutations may affect other aspects of LITAF function.
Mutations associated with CMT tend to cluster within the
CXXC knuckles that form the consensus sequence of the SLD.
This suggests that part of LITAF function resides in these regions.
However, the mechanism involved in how LITAF causes CMT
subtype 1C is unknown. It is currently unclear whether defects in
LITAF function may result in an inappropriate accumulation of
target protein, as is the case for PMP22. The fact that endogenous
LITAF localizes to aggresomes suggests that wild-type LITAF may
itself exhibit high levels of misfolding, possibly because of the
highly hydrophobic nature of the SLD. In addition, the
accumulation of misfolded proteins in the aggresome can lead to
apoptosis [31]. Mutations throughout the SLD of LITAF may
exaggerate this affect, completely overwhelming the degradation
machinery of the cell resulting in the accumulation of aggregated
LITAF protein. The possibility also exists that LITAF plays a
specific function in the aggresome, although there is currently no
evidence to support this.
Although LITAF localizes to aggresomes in BGMK cells, it is
possible that this localization is cell-type specific. We were unable
to observe endogenous LITAF in HEK-293, Hela, and primary
neuronal cell lines. One explanation for our inability to observe
endogenous LITAF in these cells is that LITAF maybe express-
ed at levels below our ability to detect LITAF by indirect
immunofluorescence. Alternatively, LITAF appears to be upre-
gulated in response to bacterial cell wall components [32,33,34].
So endogenous levels may remain undetectable until the cells are
stimulated.
There appears to be a discrepancy between the localization of
endogenous and recombinant LITAF within a cell. Recombinant
LITAF exhibits localization with late endosomes/lysosomes [1],
while we show for the first time here that endogenous LITAF
accumulates in aggresomes and this accumulation may be
mediated by the SLD in BGMK cells. One possibility for the
discrepancy in cellular localization between endogenous and
recombinant LITAF is over-expression of the recombinant
construct. If endogenous LITAF accumulates in aggresomes then
over-expression of LITAF may trigger a catabolic process called
autophagy. Autophagy is mediated by an ubiquitin-like conjuga-
tive system and intracellular material is delivered to lysosomes for
bulk degradation [35]. Autophagy is often used as a method by
cells to dispose of aggresomes and avoid the unnecessary
aggresome enlargement and saturation of degradation machinery
[36,37,38]. Over-expression of LITAF would therefore result in its
localization to lysosomes. It would be interesting to determine the
rate of degradation of LITAF in cells (in the presence and absence
of lysosome or proteasome inhibitors) to reveal whether this is the
case.
It is also possible that ectopically expressed LITAF is also found
in aggresomes. Ectopically expressed LITAF appears to be present
Figure 4. The SLD localizes to the aggresome. BGMK cells were transfected with myc-SLD. Forty-eight hours post-transfection, cells were fixed
and immunofluorescence was completed with a variety of cellular markers in order to determine localization of the SLD (green). Endogenous LITAF
was detected using an anti-LITAF antibody (red) and vimentin (anti-vimentin antibodies) and the Golgi apparatus (anti-Golgin 97) are visualized in
blue. DIC was used to visualize the cell nuclei.
doi:10.1371/journal.pone.0030003.g004
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identified as the late endosome/lysosome [2,3,4]. In addition,
ectopically expressed LITAF partially localizes with the SLD at 36
and 48 hours post transfection in all cells examined (Figure 3B).
Since the SLD is localized with vimentin in the aggresome at 48
hours (Figure 4), this suggests that ectopic LITAF may also be
localized, in part, to the aggresome. However, the bulk of the
ectopic LITAF is localized to the late endosome/lysosome.
This paper describes for the first time a novel cellular
localization for endogenous LITAF. We found using a variety of
cellular markers that endogenous LITAF accumulates in aggre-
somes. This cellular localization of LITAF was also supported by
the observation that LITAF undergoes asymmetric inheritance
during mitosis. The process of asymmetrical inheritance confers an
evolutionary advantage to one daughter cell. Furthermore, we
found that the C-terminus of LITAF may mediate this
localization. The role of LITAF in CMT further stresses the
importance of understanding how LITAF functions and what role
the aggresome plays in the development of this disease.
Materials and Methods
Reagents, cell lines, and antibodies
Baby green monkey kidney (BGMK) cells were obtained from
the American Type Culture Collection (ATCC; Manassas, VA)
and were maintained at 37uC with 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM; HyClone, Ottawa, ON)
supplemented with 7% FBS, 2 mM L-glutamine, penicillin
(100 U/mL), and streptomycin (100 mg/mL). Cells used for
immunofluorescence were transfected using a polyethylenimine
(PEI) reagent using 5 mg plasmid/10 cm
2 plate and a PEI:DNA
ratio of 4:1. Antibodies used during immunofluorescence include:
mouse polyclonal anti-LITAF antibody (dilution 1/100, BD
Biosciences, San Jose, CA); anti-Nedd4 antibodies (dilution 1/
100, BD Biosciences, Mississauga, ON); a-tubulin antibody
(dilution 1/100, Santa Cruz Biotechnology, Santa Cruz, CA);
anti-myc monoclonal antibody 9E10 myc monoclonal antibody
(dilution - 1/100, Roche, Indianapolis, IN); anti-FLAG (M2)
monoclonal antibody (dilution 1/500, Sigma, Oakville, ON); anti-
Golgin 97 (dilution 1/100, Invitrogen, Burlington, ON); and
FITC/Cy3/Cy5-conjugated goat anti-mouse or anti-rabbit im-
munoglobulin G (IgG) from Jackson ImmunoResearch Inc.
(dilutions – 1/100, 1/200, 1/100 respectively; West Grove, PA).
Expression plasmids
Full length mouse LITAF and the SLD of LITAF were
amplified using a PCR mixture containing 1X PCR buffer
(Invitrogen, Burlington, ON), 3.0 mM MgCl2, 2.5 U Taq DNA
polymerase (5 U/mL; Invitrogen), 0.2 mM forward primer,
0.2 mM reverse primer, and mouse LITAF cDNA (ATCC) as
template DNA. LITAF was amplified and a FLAG tag was added
to the N-terminus using the following forward and reverse primers:
(LITAF-forward) 59 – AAGCTTATGGATTACAAGGATGAC-
GACGATAAGTCGGTTCCAGGACCTTACC - 39, and (LITA-
F-reverse)59 – CTCGAGCTAAAAGCGTTGTAGGTG - 39. The
SLD was amplified and a myc tag was included at the N-terminus
using the following forward and reverse primers: (SLD-forward) 59 -
ATGGAACAAAAACTTATTTCTGAAGAAGATCTGGTGCA-
GACGGTCTACGTGCAG - 39 and LITAF-reverse (above). The
following cycling conditions wereused: 94uC for30 seconds, 52uCfo r
30 seconds, 72uC for 90 seconds for 30 cycles. The resulting PCR
constructs were initially cloned into the vector pGEM-T easy
(Promega, Madison, WI), followed by cloning into the XhoI and
HindIII sites of pcDNA3.1 (Invitrogen).
Immunofluorescence analysis
Cells were fixed for ten minutes in 3.7% paraformaldehyde in
PBS. Cells were washed several times in PBS and were
permeabilized in a 0.1% Triton X-100 in PBS solution for four
minutes. Following several washes in PBS, cells were blocked for
two hours at room temperature in block buffer (5% BSA (w/v),
50 mM Tris HCl (pH 7.4), 150 mM NaCl, 0.5% NP-40 (v/v).
Cells were then washed several times with wash buffer (1% BSA
(w/v), 50 mM Tris HCl (pH 7.4), 150 mM NaCl, 0.5% NP-40 (v/
v)) and were incubated for one hour at room temperature with
primary antibody diluted in wash buffer. Cells were washed
several times in wash buffer and incubated for one hour at room
temperature in darkness with secondary antibody diluted in wash
buffer. Following several more washes in wash buffer, fluorescence
was detected using a Leica DM SP2 confocal microscope (Leica,
Wetzlar, Germany) and images were assembled using Adobe
Photoshop CS4 (Adobe, San Jose, CA).
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